About Alpha-internexin
Alpha-internexin (INA) is a protein
from Homo sapiens identified by UniProt accession
Q16352, 499 residues long.
MolForge cross-references it against 0 known binders and
135 disease associations.
Target properties
| Protein name | Alpha-internexin |
| UniProt accession | Q16352 |
| Gene | INA |
| Organism | Homo sapiens |
| Length | 499 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (135)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- Abnormal brain morphology · score 0.27
- cortical surface area measurement · score 0.21
- blood phosphate measurement · score 0.19
- glomerular filtration rate · score 0.17
- pulse pressure measurement · score 0.15
- thalamus volume · score 0.11
- Myopia · score 0.11
- pathological myopia · score 0.11
- brain volume measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16352-F1 | alphafold | PREDICTED | 74.06 | — |
Amino-acid sequence (499 residues)
MSFGSEHYLC SSSSYRKVFG DGSRLSARLS GAGGAGGFRS QSLSRSNVAS SAACSSASSL GLGLAYRRPP ASDGLDLSQA AARTNEYKII RTNEKEQLQG LNDRFAVFIE KVHQLETQNR ALEAELAALR QRHAEPSRVG ELFQRELRDL RAQLEEASSA RSQALLERDG LAEEVQRLRA RCEEESRGRE GAERALKAQQ RDVDGATLAR LDLEKKVESL LDELAFVRQV HDEEVAELLA TLQASSQAAA EVDVTVAKPD LTSALREIRA QYESLAAKNL QSAEEWYKSK FANLNEQAAR STEAIRASRE EIHEYRRQLQ ARTIEIEGLR GANESLERQI LELEERHSAE VAGYQDSIGQ LENDLRNTKS EMARHLREYQ DLLNVKMALD IEIAAYRKLL EGEETRFSTS GLSISGLNPL PNPSYLLPPR ILSATTSKVS STGLSLKKEE EEEEASKVAS KKTSQIGESF EEILEETVIS TKKTEKSNIE ETTISSQKI
Explore Alpha-internexin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets